Navigation Links
Nuvelo Reports Second Quarter 2008 Financial Results
Date:7/23/2008

- 4,671 -

Total operating expenses 15,954 18,506 35,423 36,597

Operating income (loss) (892) 27,319 (20,298) 10,138

Interest income, net 661 1,723 1,659 3,555

Net income (loss) $(231) $29,042 $(18,639) $13,693

Net income (loss) per share:

Basic $(0.00) $0.54 $(0.35) $0.26

Diluted $(0.00) $0.54 $(0.35) $0.26

Shares used in computing net income

(loss) per share:

Basic 53,535 53,317 53,496 53,285

Diluted 53,535 53,349 53,496 53,300

CONSOLIDATED BALANCE SHEET DATA

(in thousands)

(unaudited)

June 30, 2008 December 31, 2007*

Cash and cash equivalents,

marketable securities

and restricted cash $76,047 $103,567

Working capital 55,446 81,799

Total assets 87,018 120,683

Non-current liabilities 18,142 34,837

Accumulated deficit (489,152) (470,513)

Total stockholders' equity 52,346 67,659

* The consolidated balance sheet data as of December 31, 2007 have been

derived from the audited financial statements.


'/>"/>
SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., REYKJAVIK, Iceland, November 24 /PRNewswi...GN ) today announced that it has received notice f...mpany,s common stock will be,suspended as of Novem...the,Securities and Exchange Commission, which will...aq, unless the company files an appeal to the Nasd...
(Date:11/24/2009)..., REYKJAVIK, Iceland, November 24 /PRNewswi...GN ) today announced the approval of all of its,"f... the District of Delaware,(the "Bankruptcy Court")...relief under Chapter 11 of the United States Bankr...he orders issued by the Bankruptcy Court allow the...
(Date:11/24/2009)... SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- Shanghai B... Administration (SFDA) has approved the,investigat...lin project,(Nodlin), an innovative insulin formul...Biolaxy to initiate its first phase I clinical stu...ic of high blood glucose and poor,metabolism. The ...
(Date:11/24/2009)...imary efficacy endpoint has been met for patients ...ancer, , QUEBEC CITY, Nov. 24 /PRNewswire-Fir...SX: AEZ) (the "Company"), a global biopharmaceutic...gy, today announced positive efficacy data from a ...conjugate, AEZS-108 (formerly AN-152), in patients...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...TON BEACH, California, and AMSTERDAM, May 28 ,Agen...s, today announced its,strong support of Genentech...ocket No. FDA-2008-P-0638-0001/CP petitions that a... scientific and regulatory standards. In response,...er of support to the U.S.,Food and Drug Administra...
...France, May 28 Poxel is a research integrated,pha...erono a division of,Merck KGaA, Germany, following...in diabetes research and development. It aims to a...ses (with a primary focus on Type 2,diabetes) from...fore,out-licensing these projects to major pharmac...
...G, Md., May 28 GenVec, Inc. (Nasdaq: GNVC ) a... agreement with a single institutional investor fo... and warrants to purchase 9,615,385 shares of its ...ants are being offered in units consisting of one ...e share of common stock at a price of $0.624 per u...
Other Biology Technology:Agendia Supports Genentech's Citizen's Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards 2Poxel SAS Set up to Find Innovative Solutions for Metabolic Diseases Management 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 2GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants 3
(Date:11/24/2009)...ands of years it has been prescribed by traditiona...rom headaches and stomach pain to fever and flu. ,... University have been able to scientifically prove... otherwise known as Brazilian mint. , Testing th...ed by researcher Graciela Rocha was able to show t...
(Date:11/24/2009)...s have crystallised a protein that may help gut ba...tein could be used by probiotic producers to ident...to people. , "Probiotics need to interact with ce...d if they attach to surfaces in the gut they are m...eir activity," says Dr Nathalie Juge from the Inst...
(Date:11/24/2009)...and the American College of Medical Toxicology (AC... publication of the Journal of Medical Toxicology...ng in March 2010. It was previously published by ...urnal of Medical Toxicology , an international, pe... science and practice of medical toxicology. The ...
Breaking Biology News(10 mins):Got a pain? -- Have a cup of Brazilian mint 2A sticky solution for identifying effective probiotics 2Springer and the American College of Medical Toxicology to work together 2Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis 52567 1Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis 52567 2Injection Reverses Heart Attack Damage 4771 1Injection Reverses Heart Attack Damage 4771 2Injection Reverses Heart Attack Damage 4771 3American Joint Replacement Registry Announced 52562 1American Joint Replacement Registry Announced 52562 2
...entified a key signaling molecule in the brain tha...g for cocaine. Their finding could offer an import...ircuiting that adaptive process. , In an article i...o Bonci and colleagues established that a short pr... region central to the adaptation to addictive dru...
...s shed more light on the multi-decade debate about...ng at them. , You don,t have to watch your legs an...are. For decades scientists have debated two optio...flow hypothesis says that the brain monitors signa...ly to contract, and uses this to predict where the...
...d "peak fish" and fishermen,s nets will be hauling...l action to stem the global tide of over fishing, ... British Columbia. Dr. Daniel Pauly says the crisi...c proof than about attitude and political will. ,...gh-profile political champion like a Bono or Mande...
Other Biology News:How the brain learns to become addicted 2How does the brain know what the right hand is doing? 2Hooked on fishing, and we're heading for the bottom, says scientist 2Hooked on fishing, and we're heading for the bottom, says scientist 3
RABBIT (BABY) COMPLEMENT LYOPHILISED from AbD Serotec
Rabbit Anti-Human ZO-1 Antibody, Unconjugated from Lab Vision
Mouse Anti-Human Myeloid Marker Monoclonal Antibody, Unconjugated, Clone BM-1 from Santa Cruz Biotechnology, Inc.
5x C'GATE STOCK STABILIZING REAGENT from AbD Serotec
Biology Products: